ethyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)benzoate | 914104-00-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)benzoate
• 英文别名: Ethyl 4-(2-(tert-butoxycarbonylamino)ethyl)benzoate；ethyl 4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]benzoate
• CAS: 914104-00-0
• 化学式: C₁₆H₂₃NO₄
• 分子量: 293.363
• InChiKey: WHLJADHORNBJPV-UHFFFAOYSA-N

物化性质

• 沸点：
  426.0±38.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)benzoate 在 lithium aluminium tetrahydride 、 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 [4-(2-Boc-氨基乙基)苯基]甲醇
  参考文献：
  名称：

  Thienopyrimidone compounds

  摘要：

  公开号：

  EP1876179B1
• 作为产物：
  描述：

  4-(2-amino-ethyl)-benzoic acid hydrochloride 在 potassium carbonate 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 ethyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)benzoate
  参考文献：
  名称：

  WO2008/156820

  摘要：

  公开号：

文献信息

• SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF
  申请人：Milestone Pharmaceuticals Inc.

  公开号：US20170312243A1

  公开（公告）日：2017-11-02

  The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

  本发明涉及使用药效学有效量的短效钙通道阻滞剂来治疗缺血性心脏病、心脏心律失常、急诊室高血压危机、手术前、手术中或手术后的高血压、再灌注后无反流现象以及与骨骼肌血流减少相关的疾病。本发明还涉及制备用于这些方法的制药组合物以及用于这些方法的工具箱。
• Thienopyrimidone compound
  申请人：Murata Toshiki

  公开号：US20100069362A1

  公开（公告）日：2010-03-18

  The present invention relates to a compound represented by the formula: wherein Ar is an optionally substituted ring; A is a spacer having a main chain of 1 to 4 atoms; B is a bond, a C 1-10 alkylene group or an oxygen atom; R 3 and R 5 are each independently a hydrogen atom or a substituent; R 4 is an optionally substituted cyclic group or an optionally substituted C 1-10 alkyl group; and R 1 and R 2 are each independently a hydrogen atom or a substituent, or R 1 and R 2 or R 1 and B are bonded to form an optionally substituted nitrogen-containing heterocycle, or R 1 and Ar are bonded to form an optionally substituted nitrogen-containing fused heterocycle, or a salt thereof. The thienopyrimidone compound of the present invention has a superior melanin-concentrating hormone receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of obesity and the like.

  本发明涉及一种化合物，其表示为以下公式： 其中，Ar是可选取代环；A是具有1到4个原子的主链间隔物；B是键合、C1-10烷基或氧原子；R3和R5各自独立地是氢原子或取代基；R4是可选取代的环状基团或可选取代的C1-10烷基基团；而R1和R2各自独立地是氢原子或取代基，或者R1和R2或R1和B被键合形成可选取代的含氮杂环，或者R1和Ar被键合形成可选取代的含氮融合杂环，或其盐。本发明的噻唑嘧啶酮化合物具有优异的黑色素浓集激素受体拮抗作用，可用作预防或治疗肥胖等药物。
• Short acting phenylalkylamine calcium channel blockers and uses thereof
  申请人：Milestone Pharmaceuticals Inc.

  公开号：US09227918B2

  公开（公告）日：2016-01-05

  The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

  本发明涉及使用药理有效量的短效钙通道阻滞剂化合物来治疗缺血性心脏病、心脏心律失常、急诊室高血压危机、手术前、期间或后的高血压、再灌注后的无反流现象以及与骨骼肌血流减少相关的疾病。本发明还涉及用于上述方法的制剂的制备以及用于该方法的工具包。
• Electrophotochemical Metal‐Catalyzed Decarboxylative Coupling of Aliphatic Carboxylic Acids
  作者：Kai Yang、Jiaqing Lu、Liubo Li、Sanzhong Luo、Niankai Fu

  DOI：10.1002/chem.202202370

  日期：2022.12.15

  Convergent paired metal electrocatalysis enables the direct use of simple primary and secondary aliphatic acids as coupling partners for C(sp2)−C(sp3) bond formation by radical decarboxylation. This new electrophotocatalytic method features a broad substrate scope, wide functional-group tolerance, and could be used for late-stage functionalization of complex molecules.

  收敛配对金属电催化能够直接使用简单的初级和次级脂肪酸作为通过自由基脱羧形成C(sp 2 )−C(sp 3 ) 键的偶联伙伴。这种新的电光催化方法具有广泛的底物范围和广泛的官能团耐受性，可用于复杂分子的后期功能化。
• THIENOPYRIMIDONE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1876179A1

  公开（公告）日：2008-01-09

  The present invention relates to a compound represented by the formula: wherein Ar is an optionally substituted ring; A is a spacer having a main chain of 1 to 4 atoms; B is a bond, a C1-10 alkylene group or an oxygen atom; R3 and R5 are each independently a hydrogen atom or a substituent; R4 is an optionally substituted cyclic group or an optionally substituted C1-10 alkyl group; and R1 and R2 are each independently a hydrogen atom or a substituent, or R1 and R2 or R1 and B are bonded to form an optionally substituted nitrogen-containing heterocycle, or R1 and Ar are bonded to form an optionally substituted nitrogen-containing fused heterocycle, or a salt thereof. The thienopyrimidone compound of the present invention has a superior melanin-concentrating hormone receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of obesity and the like.

  本发明涉及一种由式表示的化合物： 其中 Ar 是任选取代的环； A 是具有 1 至 4 个原子主链的间隔物 B 是键、C1-10 亚烷基或氧原子； R3 和 R5 各自独立地为氢原子或取代基； R4 是任选取代的环状基团或任选取代的 C1-10 烷基；以及 R1 和 R2 各自独立地为氢原子或取代基，或 R1 和 R2 或 R1 和 B 键合形成任选取代的含氮杂环，或 R1 和 Ar 键合形成任选取代的含氮融合杂环或其盐。本发明的噻吩嘧啶酮化合物具有优异的黑色素浓缩激素受体拮抗作用，可用作预防或治疗肥胖症等的药物。